DDInter1731 DDInter1676
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Sunitinib {u} (Compound) resembles {v} (Compound) Metoclopramide
Sunitinib {u} (Compound) treats {v} (Disease) pancreatic cancer
Sunitinib {u} (Compound) binds {v} (Gene) SBK1
Sunitinib {u} (Compound) upregulates {v} (Gene) CRIP1
Sunitinib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Sunitinib {u} (Compound) downregulates {v} (Gene) INTS3
Sunitinib {u} (Compound) causes {v} (Side Effect) Candida infection
Sunitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etravirine
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isoprenaline
Sunitinib (Compound) resembles Metoclopramide (Compound)
Sunitinib (Compound) treats pancreatic cancer (Disease)
Sunitinib (Compound) binds SBK1 (Gene)
Sunitinib (Compound) upregulates CRIP1 (Gene)
Sunitinib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Sunitinib (Compound) downregulates INTS3 (Gene)
Sunitinib (Compound) causes Candida infection (Side Effect)
Sunitinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline